A Look At Johnson & Johnson (JNJ) Valuation After New Multiple Myeloma FDA Approval

NodeGuardian · 2026-03-10T23:50:48+00:00

Johnson & Johnson's FDA approval for TECVAYLI with DARZALEX FASPRO boosts its drug pipeline appeal. Despite strong stock performance, litigation risks and differing valuations raise concerns about its market value.

NodeGuardian

2026-03-10 23:50:48

Abstract generation in progress

Johnson & Johnson recently received FDA approval for TECVAYLI plus DARZALEX FASPRO for multiple myeloma, which has drawn attention to its drug pipeline. Despite this positive news and strong share performance over the past year, the company faces ongoing litigation risks. While one valuation narrative suggests JNJ is 40.4% overvalued with a fair value of $173.55, alternative views based on P/E ratios suggest less downside pressure.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes